What is VIVUS?
VIVUS is a focused organization dedicated to advancing innovative new therapies for patients with serious medical conditions and life-limiting diseases. Leveraging demonstrated clinical development and commercialization expertise, the company concentrates on developing high-potential molecules with compelling safety and efficacy profiles. VIVUS aims to transform these molecules into proprietary products that represent significant advances in patient care and outcomes, thereby improving patient quality of life and providing healthcare providers with new treatment options.
How much funding has VIVUS raised?
VIVUS has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in VIVUS
PPP
Public-Private Partnership
What's next for VIVUS?
The recent major strategic investment suggests VIVUS is entering a critical scaling phase, likely to accelerate the development and commercialization of its therapeutic pipeline. This enterprise-level funding will empower the company to further its mission of addressing unmet medical needs, potentially expanding its clinical trials, enhancing its manufacturing capabilities, and strengthening its market presence. The strategic nature of the investment indicates a strong belief from backers in VIVUS's long-term vision and its capacity to deliver value to shareholders and patients alike.
See full VIVUS company page
